COPENHAGEN, Denmark - Novo Nordisk reported on Nov. 16 in the New England Journal of Medicine that nearly 80% of obese children aged 6 to 11 cut their body mass index by 10% or more on Wegovy. After 68 weeks, 40.4% of treated children were no longer classified as having obesity, compared with zero on placebo.
Phase 3 Trial Delivers Sharp BMI Drops
The STEP Young trial enrolled 167 children aged 6 to under 12, assigning 112 to weekly 1.7 mg or 2.4 mg semaglutide injections and 55 to placebo alongside diet and exercise counseling. Under the efficacy estimand, BMI fell 17.4% on Wegovy versus a 2.2% rise on placebo, with 78.7% of treated children achieving at least a 10% reduction. Regardless of adherence, BMI dropped 13.5% versus a 2.7% increase on placebo.
Addressing a Pediatric Treatment Gap
Wegovy is currently approved in the U.S. only for patients aged 12 and older, leaving few approved medication options for younger children with non-genetic obesity. "Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child's trajectory back towards one of improving weight related health," said Dr. Ania M. Jastreboff of Yale University. Novo Nordisk reported no new concerns regarding growth or pubertal development.
Regulatory Filing Path for Under-12 Use
Wegovy remains unapproved for children under 12, and Novo Nordisk has not announced an exact filing date. Regulators are expected to review the full STEP Young safety and efficacy dataset as Novo competes with Eli Lilly in pediatric and adult obesity care.



